Abstract:Japanese encephalitis virus (JEV), an arthropod-borne flavivirus, is a major cause of acute viral encephalitis in humans. No approved drug is available for the specific treatment of JEV infections, and the available vaccines are not effective against all clinical JEV isolates. In the study described here, a high-throughput screening of an FDA-approved drug library for inhibitors of JEV was performed. Five hit drugs that inhibited JEV infection with a selective index of >10 were identified. The antiviral activities of these five hit drugs against other flavivirus, including Zika virus, were also validated. As three of the five hit drugs were calcium inhibitors, additional types of calcium inhibitors that confirmed that calcium is essential for JEV infection, most likely during viral replication, were utilized. Adaptive mutant analysis uncovered that replacement of Q130, located in transmembrane domain 3 of the nonstructural NS4B protein, which is relatively conserved in flaviviruses, with R or K conferred JEV resistance to manidipine, a voltage-gated Ca2(+) channel (VGCC) inhibitor, without an apparent loss of the viral growth profile. Furthermore, manidipine was indicated to protect mice against JEV-induced lethality by decreasing the viral load in the brain, while it abrogated the histopathological changes associated with JEV infection. This study provides five antiflavivirus candidates and identifies cytoplasmic calcium to be a novel antiviral target for the treatment of JEV infection. The findings reported here provide therapeutic possibilities for combating infections caused by flaviviruses. IMPORTANCE No approved therapy for the treatment of Japanese encephalitis virus infection is currently available. Repurposing of approved drugs would accelerate the development of a therapeutic stratagem. In this study, we screened a library of FDA-approved drugs and identified five hit drugs, especially calcium inhibitors, exerting antiflavivirus activity that blocked viral replication. The in vivo efficacy and toxicity of manidipine were investigated with a mouse model of JEV infection, and the viral target was identified by generating an adaptive mutant. KEYWORDS FDA-approved drugs, Japanese encephalitis virus, NS4B, flavivirus, high-throughput screening, manidipine

RNAi screening reveals requirement for PDGFRβ in JEV infection

Rna Interference Screening Reveals Requirement For Platelet-Derived Growth Factor Receptor Beta In Japanese Encephalitis Virus Infection

Effective Inhibition of Japanese Encephalitis Virus Replication by Shrnas Targeting Various Viral Genes in Vitro and in Vivo.

CRISPR screening of porcine sgRNA library identified host factors essential for Japanese encephalitis virus replication

EGFR Activation Impairs Antiviral Activity of Interferon Signaling in Brain Microvascular Endothelial Cells During Japanese Encephalitis Virus Infection

Ezrin is Essential for the Entry of Japanese Encephalitis Virus into the Human Brain Microvascular Endothelial Cells.

CRISPR Screening of Porcine Sgrna Library Identifies Host Factors Associated with Japanese Encephalitis Virus Replication

Screening of Natural Extracts for Inhibitors Against Japanese Encephalitis Virus Infection

Circular RNA network plays a potential antiviral role in the early stage of JEV infection in mouse brain

Japanese encephalitis virus restricts HMGB1 expression to maintain MAPK pathway activation for viral replication

Japanese Encephalitis Virus NS1′ Protein Interacts with Host CDK1 Protein to Regulate Antiviral Response

Role of the NLRP3/caspase-1/GSDMD signaling pathway in dopaminergic neurons during Japanese encephalitis virus infection

Single-cell RNA sequencing reveals the immune features and viral tropism in the central nervous system of mice infected with Japanese encephalitis virus

Identification And Analysis Of Differentially-Expressed Micrornas In Japanese Encephalitis Virus-Infected Pk-15 Cells With Deep Sequencing

Lentivirus-mediated RNA Interference Against Japanese Encephalitis Virus Infection in Vitro and in Vivo.

Screening of FDA-Approved Drugs for Inhibitors against Japanese Encephalitis Virus Infection.

The NS3 and NS4A Genes As the Targets of RNA Interference Inhibit Replication of Japanese Encephalitis Virus in Vitro and in Vivo.

Microarray Analysis Identifies the Potential Role of Long Non-Coding RNA in Regulating Neuroinflammation during Japanese Encephalitis Virus Infection.

Mir-124 Attenuates Japanese Encephalitis Virus Replication by Targeting DNM2

Japanese encephalitis virus infection induces changes of mRNA profile of mouse spleen and brain

Quantitative Phosphoproteomic Analysis Identifies the Critical Role of JNK1 in Neuroinflammation Induced by Japanese Encephalitis Virus